Min Chong Kim, Eun Yoon Cho, So Yeon Park, Hee Jin Lee, Ji Shin Lee, Jee Yeon Kim, Ho-chang Lee, Jin Ye Yoo, Hee Sung Kim, Bomi Kim, Wan Seop Kim, Nari Shin, Young Hee Maeng, Hun Soo Kim, Sun Young Kwon, Chungyeul Kim, Sun-Young Jun, Gui Young Kwon, Hye Jeong Choi, So Mang Lee, Ji Eun Choi, Ae Ri An, Hyun Joo Choi, EunKyung Kim, Ahrong Kim, Ji-Young Kim, Jeong Yun Shim, Gyungyub Gong, Young Kyung Bae
Cancer Res Treat. 2024;56(4):1096-1104. Published online March 6, 2024
Purpose Notable effectiveness of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)–low advanced breast cancer (BC) has focused pathologists’ attention. We studied the incidence and clinicopathologic characteristics of HER2-low BC, and the effects of immunohistochemistry (IHC) associated factors on HER2 IHC results.
Materials and Methods The Breast Pathology Study Group of the Korean Society of Pathologists conducted a nationwide study using real-world data on HER2 status generated between January 2022 and December 2022. Information on HER2 IHC protocols at each participating institution was also collected.
Results Total 11,416 patients from 25 institutions included in this study. Of these patients, 40.7% (range, 6.0% to 76.3%) were classified as HER2-zero, 41.7% (range, 10.5% to 69.1%) as HER2-low, and 17.5% (range, 6.7% to 34.0%) as HER2-positive. HER2-low tumors were associated with positive estrogen receptor and progesterone receptor statuses (p < 0.001 and p < 0.001, respectively). Antigen retrieval times (≥ 36 minutes vs. < 36 minutes) and antibody incubation times (≥ 12 minutes vs. < 12 minutes) affected on the frequency of HER2 IHC 1+ BC at institutions using the PATHWAY HER2 (4B5) IHC assay and BenchMark XT or Ultra staining instruments. Furthermore, discordant results between core needle biopsy and subsequent resection specimen HER2 statuses were observed in 24.1% (787/3,259) of the patients.
Conclusion The overall incidence of HER2-low BC in South Korea concurs with those reported in previously published studies. Significant inter-institutional differences in HER2 IHC protocols were observed, and it may have impact on HER2-low status. Thus, we recommend standardizing HER2 IHC conditions to ensure precise patient selection for targeted therapy.
Citations
Citations to this article as recorded by
Impact of immunohistochemistry staining conditions on the incidence of human epidermal growth factor receptor 2 (HER2)-low breast cancer Min Chong Kim, Sun Young Kwon, Hye Ra Jung, Young Kyung Bae Virchows Archiv.2024;[Epub] CrossRef
Breast Cancer: Extracellular Matrix and Microbiome Interactions Lourdes Herrera-Quintana, Héctor Vázquez-Lorente, Julio Plaza-Diaz International Journal of Molecular Sciences.2024; 25(13): 7226. CrossRef
Purpose Breast cancer is one of the most common causes of cancer-related death in females. Numerous drug-targetable biomarkers and predictive biomarkers have been developed. Some researchers have expressed doubts about the need for next-generation sequencing (NGS) studies in daily practice. This study analyzed the results of NGS studies on breast cancer at a single institute and evaluated the real-world applications of NGS data to precision medicine for breast cancer.
Materials and Methods We retrospectively collected the results of NGS studies and analyzed the histopathologic features and genetic profiles of patients treated for breast cancer from 2010 to 2021. Seventy cases had data from CancerSCAN, a customized panel of 375 cancer-associated genes, and 110 cases had data from TruSight Oncology 500.
Results The most frequently detected single nucleotide variant was the TP53 mutation (123/180, 68.3%), followed by PIK3CA mutations (51/180, 28.3%). Estrogen receptor 1 (ESR1) mutation was detected in 11 patients (6.1%), of whom 10 had hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer, and two had no history of prior endocrine therapy. Based on their NGS study results, 13 patients (7.2%) received target therapy. Among them, four patients had a BRCA1 or BRCA2 germline mutation, and nine patients had a PIK3CA mutation.
Conclusion NGS can provide information about predictive biomarkers and drug-targetable biomarkers that can enable treatment and participation in clinical trials based on precision medicine. Further studies should be conducted to excavate novel drug-targetable biomarkers and develop additional target therapies.
Citations
Citations to this article as recorded by
Detection of EGFR exon 20 insertion mutations in non-small cell lung cancer: implications for consistent nomenclature in precision medicine Jieun Park, Boram Lee, Ji-Young Song, Minjung Sung, Mi Jeong Kwon, Chae Rin Kim, Sangjin Lee, Young Kee Shin, Yoon-La Choi Pathology.2024; 56(5): 653. CrossRef
Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer Elena Guerini-Rocco, Konstantinos Venetis, Giulia Cursano, Eltjona Mane, Chiara Frascarelli, Francesco Pepe, Mariachiara Negrelli, Edoardo Olmeda, Davide Vacirca, Alberto Ranghiero, Dario Trapani, Carmen Criscitiello, Giuseppe Curigliano, Christian Rolfo, Critical Reviews in Oncology/Hematology.2024; 201: 104427. CrossRef
An ultra-sensitive and rapid immunosensor for the onsite detection of circulating tumor DNA in breast cancer Yi Bi, Xiao Lv, Ke Wang, Jinyu Wu, Xiang Shi, Xiaodong Zheng, Xiaogang Lin Frontiers in Bioengineering and Biotechnology.2024;[Epub] CrossRef
NGS mutational status on first diagnostic tissue, liquid biopsy and mastectomy in G2–G3 breast cancer Carmen Maria Ardeleanu, Maria Victoria Olinca , Cristian Gabriel Viişoreanu , Horaţiu Alin Mureşan , Adriana Tecuceanu-Vulpe , Georgiana Manole , Iulia Elena Gune , Bianca Gălăţeanu , Andreea-Corina Ilie-Petrov Romanian Journal of Morphology and Embryology.2024; 65(2): 195. CrossRef
Ji-Yeon Kim, Kyunghee Park, Hae Hyun Jung, Eunjin Lee, Eun Yoon Cho, Kwang Hee Lee, Soo Youn Bae, Se Kyung Lee, Seok Won Kim, Jeong Eon Lee, Seok Jin Nam, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Cancer Res Treat. 2016;48(4):1338-1350. Published online February 18, 2016
Purpose TP53, the most frequently mutated gene in breast cancer, is more frequently altered in HER2-enriched and basal-like breast cancer. However, no studies have clarified the role of TP53 status as a prognostic and predictive marker of triple-negative breast cancer (TNBC).
Materials and Methods
We performed p53 immunohistochemistry (IHC), nCounter mRNA expression assay, and DNA sequencing to determine the relationship between TP53 alteration and clinical outcomes of TNBC patients.
Results
Seventy-seven of 174 TNBC patients were found to harbor a TP53 mutation. Patients with missense mutations showed high protein expression in contrast to patients with deletion mutations (positivity of IHC: wild type vs. missense vs. deletion mutation, 53.6% vs. 89.8% vs. 25.0%, respectively; p < 0.001). TP53 mRNA expression was influenced by mutation status (mRNA expression [median]: wild type vs. missense vs. deletion mutation, 207.36± 132.73 vs. 339.61±143.21 vs. 99.53±99.57,respectively; p < 0.001). According to survival analysis, neither class of mutation nor protein or mRNA expression status had any impact on patient prognosis. In subgroup analysis, low mRNA expression was associated with poor prognosis in patientswith a TP53 missense mutation (5-year distantrecurrence-free survival [5Y DRFS]: low vs. high, 50.0% vs. 87.8%; p=0.009), while high mRNA expression with a TP53 deletion mutation indicated poor prognosis (5Y DRFS: low vs. high, 91.7% vs. 75.0%; p=0.316).
Conclusion
Association between TP53 mutation and expression indicates a potential prognostic marker of TNBC; hence both DNA sequencing and mRNA expression analysis may be required to predict the prognosis of TNBC patients.
Citations
Citations to this article as recorded by
Immunohistochemical Characterization of a Large Cohort of Triple Negative Breast Cancer Rachel Han, Sharon Nofech-Mozes, Dina Boles, Hannah Wu, Nikolina Curcin, Elzbieta Slodkowska International Journal of Surgical Pathology.2024; 32(2): 239. CrossRef
Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice Laura Lopez-Gonzalez, Alicia Sanchez Cendra, Cristina Sanchez Cendra, Eduardo David Roberts Cervantes, Javier Cassinello Espinosa, Tatiana Pekarek, Oscar Fraile-Martinez, Cielo García-Montero, Ana María Rodriguez-Slocker, Laura Jiménez-Álvarez, Luis G. Gu Medicina.2024; 60(1): 168. CrossRef
TP53R175H mutation promotes breast cancer cell proliferation through CORO1A–P38 MAPK pathway regulation Yali Su, Jiaxuan Zhao, Haoran Fu, Zeliang Liu, Panyan Du, Jianxia Zheng, Jinghua Wu, Jinghua Zhang Biochemical Pharmacology.2024; 221: 116047. CrossRef
TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer Akiko Arimura, Kazuko Sakai, Kazuhisa Kaneshiro, Takafumi Morisaki, Saori Hayashi, Kimihisa Mizoguchi, Mai Yamada, Masaya Kai, Mayumi Ono, Kazuto Nishio, Masafumi Nakamura, Makoto Kubo Cancers.2024; 16(6): 1184. CrossRef
Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy Zhijun Li, Yiqun Han, Jiayu Wang, Binghe Xu Journal of Personalized Medicine.2023; 13(2): 190. CrossRef
The role of p53 and ki67 in predicting clinical outcome in breast cancer patients Bhanu Prakash Lalkota, B.J Srinivasa, Mani V. Swamy, Diganta Hazarika, B.M Jeet, K Jyothi, Mithua Ghosh, Suhail M. Sayeed, Mohammad Nasiruddin, Radheshyam Naik Journal of Cancer Research and Therapeutics.2023; 19(2): 208. CrossRef
Novel microtubule inhibitor SQ overcomes multidrug resistance in MCF-7/ADR cells by inhibiting BCRP function and mediating apoptosis Xing Chang, Zi Liu, Simeng Cao, Jiang Bian, Dayong Zheng, Nuo Wang, Qi Guan, Yingliang Wu, Weige Zhang, Zengqiang Li, Daiying Zuo Toxicology and Applied Pharmacology.2022; 436: 115883. CrossRef
Targeted gene next‐generation sequencing reveals genomic profile in a cohort of 46 Chinese patients with breast cancer Jie Yao, Qian Chen, Jun‐qi Zhu, Rui‐gang Cai The Journal of Gene Medicine.2022;[Epub] CrossRef
Effect of the elastin-derived peptides (VGVAPG and VVGPGA) on breast (MCF-7) and lung (A549) cancer cell lines in vitro Konrad A. Szychowski, Bartosz Skóra, Tadeusz Pomianek Biomedicine & Pharmacotherapy.2022; 151: 113149. CrossRef
p53 Missense Mutation is Associated with Immune Cell PD-L1 Expression in Triple-Negative Breast Cancer Ai-Yan Xing, Long Liu, Ke Liang, Bin Wang Cancer Investigation.2022; 40(10): 879. CrossRef
Checkpoint Kinase 1 (CHK1) Functions as Both a Diagnostic Marker and a Regulator of Epithelial-to-Mesenchymal Transition (EMT) in Triple-Negative Breast Cancer Hyo-Jin Kim, Bo-Gyeong Seo, Eun-Chan Seo, Kwang-Min Lee, Cheol Hwangbo Current Issues in Molecular Biology.2022; 44(12): 5848. CrossRef
An integrative pan-cancer analysis of COPB1 based on data mining Heyan Chen, Kunlong Li, Yijun Li, Peilin Xie, Jianjun He, Huimin Zhang Cancer Biomarkers.2021; 30(1): 13. CrossRef
Sex differences in expression of immune elements emerge in children, young adults and mice with osteosarcoma Lauren J. Mills, Logan G. Spector, David A. Largaespada, Lindsay A. Williams Biology of Sex Differences.2021;[Epub] CrossRef
GATA3 as an Adjunct Prognostic Factor in Breast Cancer Patients with Less Aggressive Disease: A Study with a Review of the Literature Patrizia Querzoli, Massimo Pedriali, Rosa Rinaldi, Paola Secchiero, Paolo Giorgi Rossi, Elisabetta Kuhn Diagnostics.2021; 11(4): 604. CrossRef
Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis Dharambir Kashyap, Vivek Kumar Garg, Elise N. Sandberg, Neelam Goel, Anupam Bishayee Pharmaceutics.2021; 13(4): 569. CrossRef
Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer Weikai Xiao, Guochun Zhang, Bo Chen, Xiaoqing Chen, Lingzhu Wen, Jianguo Lai, Xuerui Li, Min Li, Hao Liu, Jing Liu, Han Han-Zhang, Analyn Lizaso, Ning Liao Frontiers in Oncology.2021;[Epub] CrossRef
Syndrome de Peutz–Jeghers et surveillance mammaire : les nouvelles recommandations à propos d’une observation M. Osada, P. Maniez, N. Taris, C. Mathelin Gynécologie Obstétrique Fertilité & Sénologie .2021; 49(10): 795. CrossRef
Curcumin: Modulator of Key Molecular Signaling Pathways in Hormone-Independent Breast Cancer Reyhaneh Farghadani, Rakesh Naidu Cancers.2021; 13(14): 3427. CrossRef
Effect of Dickkopf-1 (Dkk-1) and SP600125, a JNK Inhibitor, on Wnt Signaling in Canine Prostate Cancer Growth and Bone Metastases Wachiraphan Supsavhad, Bardes B. Hassan, Jessica K. Simmons, Wessel P. Dirksen, Said M. Elshafae, Nicole A. Kohart, Aylin A. Demirer, Thomas J. Rosol Veterinary Sciences.2021; 8(8): 153. CrossRef
TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines Ashkan Shahbandi, Hoang D. Nguyen, James G. Jackson Trends in Cancer.2020; 6(2): 98. CrossRef
The novel TP53 3′-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection Feng Zeng, Jianfu Heng, Xinwu Guo, Yue Wang, Wenhan Wu, Lili Tang, Min Chen, Shouman Wang, Hongyu Deng, Jun Wang Breast Cancer Research and Treatment.2020; 180(1): 237. CrossRef
Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China Zongbi Yi, Fei Ma, Guohua Rong, Yanfang Guan, Chunxiao Li, Binghe Xu Cancer Communications.2020; 40(6): 260. CrossRef
Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer Gu Xiao, Devon Lundine, George K. Annor, Jorge Canar, Viola Ellison, Alla Polotskaia, Patrick L. Donabedian, Thomas Reiner, Galina F. Khramtsova, Olufunmilayo I. Olopade, Alexander Mazo, Jill Bargonetti Cancer Research.2020; 80(3): 394. CrossRef
Genomic analysis of racial differences in triple negative breast cancer Chang-Sheng Chang, Eiko Kitamura, Joan Johnson, Roni Bollag, Lesleyann Hawthorn Genomics.2019; 111(6): 1529. CrossRef
p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy Hyeon Jeong Oh, Jeong Mo Bae, Xianyu Wen, Seorin Jung, Younghoon Kim, Kyung Ju Kim, Nam-Yun Cho, Jung Ho Kim, Sae-Won Han, Tae-You Kim, Gyeong Hoon Kang British Journal of Cancer.2019; 120(8): 797. CrossRef
Immunostaining for p53 and p16CDKN2A Protein Is Not Predictive of Prognosis for Dogs with Malignant Mammary Gland Neoplasms John S Munday, Harsha Ariyarathna, Danielle Aberdein, Neroli A Thomson Veterinary Sciences.2019; 6(1): 34. CrossRef
NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer Paul B. Mullan, Victoria Bingham, Paula Haddock, Gareth W. Irwin, Elaine Kay, Stephen McQuaid, Niamh E. Buckley BMC Cancer.2019;[Epub] CrossRef
Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma Jing-ping Li, Xiang-mei Zhang, Zhenzhen Zhang, Li-hua Zheng, Sonali Jindal, Yun-jiang Liu Medicine.2019; 98(18): e15449. CrossRef
Elevated levels of eEF1A2 protein expression in triple negative breast cancer relate with poor prognosis Fabiola Giudici, Elisabetta Petracci, Oriana Nanni, Cristina Bottin, Maurizio Pinamonti, Fabrizio Zanconati, Bruna Scaggiante, Aamir Ahmad PLOS ONE.2019; 14(6): e0218030. CrossRef
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00 Elisabetta Munzone, Kathryn P. Gray, Caterina Fumagalli, Elena Guerini-Rocco, István Láng, Thomas Ruhstaller, Lorenzo Gianni, Roswitha Kammler, Giuseppe Viale, Angelo Di Leo, Alan S. Coates, Richard D. Gelber, Meredith M. Regan, Aron Goldhirsch, Massimo B Breast Cancer Research and Treatment.2018; 170(2): 351. CrossRef
Cold atmospheric plasma conveys selectivity on triple negative breast cancer cells both in vitro and in vivo Liangjian Xiang, Xiaoyu Xu, Shuo Zhang, Dongyan Cai, Xiaofeng Dai Free Radical Biology and Medicine.2018; 124: 205. CrossRef
Genetic Markers in Triple-Negative Breast Cancer Zuzana Sporikova, Vladimira Koudelakova, Radek Trojanec, Marian Hajduch Clinical Breast Cancer.2018; 18(5): e841. CrossRef
Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy‐treated triple negative breast cancer Soo Youn Bae, Seung Pil Jung, Se Kyung Lee, Jonghan Yu, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam The Kaohsiung Journal of Medical Sciences.2018; 34(12): 663. CrossRef
Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer Yanli Luo, Wentao Huang, Huizhen Zhang, Guang Liu Oncology Letters.2018;[Epub] CrossRef
P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients Yunbao Pan, Yufen Yuan, Guoshi Liu, Yongchang Wei, William B. Coleman PLOS ONE.2017; 12(2): e0172324. CrossRef
Alcohol promotes migration and invasion of triple‐negative breast cancer cells through activation of p38 MAPK and JNK Ming Zhao, Erin W. Howard, Amanda B. Parris, Zhiying Guo, Qingxia Zhao, Xiaohe Yang Molecular Carcinogenesis.2017; 56(3): 849. CrossRef
Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis Zongbi Yi, Fei Ma, Chunxiao Li, Rongrong Chen, Lifang Yuan, Xiaoying Sun, Xiuwen Guan, Lixi Li, Binliang Liu, Yanfang Guan, Haili Qian, Binghe Xu Scientific Reports.2017;[Epub] CrossRef
TP53 gene expression levels and tumor aggressiveness in canine mammary carcinomas Táya F. Oliveira, Tábata Maués, Mariana S. Ramundo, Agnes Marie S. Figueiredo, Marcela F. V. de Mello, Kênia B. El-Jaick, Maria de Lourdes G. Ferreira, Ana Maria R. Ferreira Journal of Veterinary Diagnostic Investigation.2017; 29(6): 865. CrossRef
Overexpression of p53 protein is a marker of poor prognosis in Mexican women with breast cancer Jisela Dimas-González, Vilma Maldonado-Lagunas, José Díaz-Chávez, María Eugenia López-Arellano, José Muñoz-Camacho, Marco Antonio Terán-Porcayo, Alfredo Lagunas-Martínez Oncology Reports.2017; 37(5): 3026. CrossRef
Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing Xi-Xi Chen, Qian Zhong, Yang Liu, Shu-Mei Yan, Zhang-Hua Chen, Shan-Zhao Jin, Tian-Liang Xia, Ruo-Yan Li, Ai-Jun Zhou, Zhe Su, Yu-Hua Huang, Qi-Tao Huang, Li-Yun Huang, Xing Zhang, Yan-Na Zhao, Jin-Ping Yun, Qiu-Liang Wu, Dong-Xin Lin, Fan Bai, Mu-Sheng Z Nature Communications.2017;[Epub] CrossRef
Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes Ji-Yeon Kim, Eunjin Lee, Kyunghee Park, Woong-Yang Park, Hae Hyun Jung, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park Oncotarget.2017; 8(17): 27997. CrossRef
miR-34a expression in human breast cancer is associated with drug resistance Zhi-Hua Li, Xueling Weng, Qiu-Yun Xiong, Jian-Hong Tu, An Xiao, Wei Qiu, Yu Gong, Er-Wei Hu, Songyin Huang, Ya-Li Cao Oncotarget.2017; 8(63): 106270. CrossRef
Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer Min Chong Kim, Jung Eun Choi, Soo Jung Lee, Young Kyung Bae Annals of Surgical Oncology.2016; 23(11): 3524. CrossRef
2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway Jingwen Xu, Mengting Han, Jiwei Shen, Qi Guan, Zhaoshi Bai, Binyue Lang, Huijuan Zhang, Zengqiang Li, Daiying Zuo, Weige Zhang, Yingliang Wu Cancer Letters.2016; 383(1): 9. CrossRef
Su Jin Lee, Silvia Park, Hee Kyung Ahn, Jun Ho Yi, Eun Yoon Cho, Jong Mu Sun, Jeong Eon Lee, Seok Jin Nam, Jung-Hyun Yang, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im
Cancer Res Treat. 2011;43(2):89-95. Published online June 30, 2011
PURPOSE The aim of the current study was to determine the incidence, clinical presentation, and treatment outcomes of "bone-only metastases" in patients with breast cancer and to analyze the impact of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status on prognosis. MATERIALS AND METHODS Between 1994 and 2007, of 968 patients with metastatic breast cancer who underwent palliative management at Samsung Medical Center, 565 (57%) relapsed with distant metastases. Of the 968, 146 (15%) had bone-only metastases during a median follow-up period of 75 months. Among the 146 patients with bone-only metastases, 122 (84%) were relapsed patients after curative surgery and 24 (26%) were initially metastatic cases. RESULTS The median time from primary surgery to bone-only metastases of the 122 patients was 37 months (95% confidence interval [CI], 27 to 46 months). Bone-only metastases were more common in the HR-positive group than in the other subtypes (85% for HR+; 8.2% for HER2+; 6.8% for triple negative. Among all 146 patients, 75 (51%) were treated with hormone therapy. The median post-relapse progression-free survival was 15 months (95%CI, 13 to 17 months). The median overall survival was much longer in the HR+ patients than the HER2+ and triple negative breast cancer patients with marginal statistical significance (65 vs. 40 vs. 40 months, p=0.077). CONCLUSION Breast cancer patients with "bone-only metastases" had excellent clinical outcomes. Further study is now warranted to reveal the underlying biology that regulates the behavior of this indolent tumor, as it should identify 'favorable tumor characteristics' in addition to 'favorable preferential metastatic site.'
Citations
Citations to this article as recorded by
Intersecting Paths: Unraveling the Complex Journey of Cancer to Bone Metastasis Nour Arakil, Shahid Akhtar Akhund, Basant Elaasser, Khalid S. Mohammad Biomedicines.2024; 12(5): 1075. CrossRef
Germacrone alleviates breast cancer‐associated osteolysis by inhibiting osteoclastogenesis via inhibition of MAPK/NF‐κB signaling pathways Zhengjun Lin, Yaocheng Yang, Tang Liu, Ziyi Wu, Xianghong Zhang, Jing Yang Phytotherapy Research.2024; 38(6): 2860. CrossRef
Acro metastasis: A rare presentation in a common cancer Ali Ghanei-Shahmirzadi, Nasrin Namdari, Maral Mokhtari, Pooya Iranpour Current Problems in Cancer: Case Reports.2024; 14: 100292. CrossRef
Concise review: breast cancer stems cells and their role in metastases Mohammad Kamalabadi Farahani, Mohammad Farjadmehr, Amir Atashi, Alireza Momeni, Mahin Behzadifard Annals of Medicine & Surgery.2024; 86(9): 5266. CrossRef
Management of Oligometastatic Breast Cancer: An Expert Committee’s Opinion Dominique Leblanc, Guy Cantin, Alexandra Desnoyers, Jean Dufresne, Giuseppina Laura Masucci, Valérie Panet-Raymond, Éric Poirier, Sara Soldera, Isabelle Gingras Current Oncology.2023; 30(2): 1416. CrossRef
Surgery in the Setting of Metastatic Breast Cancer Jennifer K. Plichta, Mahsa Taskindoust, Rachel A. Greenup Current Breast Cancer Reports.2023; 15(1): 37. CrossRef
Team Approach: Management of Pathologic Fractures Aws Hammad, Osman Ahmed, Philip P. Connell, Daniel Olson, Tessa Balach JBJS Reviews.2023;[Epub] CrossRef
Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study Gianluca Bottoni, Francesco Fiz, Matteo Puntoni, Federica Matteucci, Manuela Monti, Andrea DeCensi, Oriana Nanni, Etienne Brain, Jean Louis Alberini, Bassam Dib, Gianmauro Sacchetti, Pierpaolo Trimboli, Giorgio Treglia, Nadia Harbeck, Simona Sola, Alessan European Journal of Nuclear Medicine and Molecular Imaging.2023; 50(8): 2477. CrossRef
Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort Alexandre Prieur, Andrew Harper, Momtafin Khan, Bérengère Vire, Dominique Joubert, Léa Payen, Karen Kopciuk BMC Cancer.2023;[Epub] CrossRef
SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches Qiuyao Wu, Pu Tian, Dasa He, Zhenchang Jia, Yunfei He, Wenqian Luo, Xianzhe Lv, Yuan Wang, Peiyuan Zhang, Yajun Liang, Wenjin Zhao, Jun Qin, Peng Su, Yi-Zhou Jiang, Zhi-Ming Shao, Qifeng Yang, Guohong Hu Cell Research.2023; 33(6): 464. CrossRef
Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer Mónica Cejuela, Ana Gil-Torralvo, M. Ángeles Castilla, M. Ángeles Domínguez-Cejudo, Alejandro Falcón, Marta Benavent, Sonia Molina-Pinelo, Manuel Ruiz-Borrego, Javier Salvador Bofill International Journal of Molecular Sciences.2023; 24(10): 8488. CrossRef
Multidimensional analysis to elucidate the possible mechanism of bone metastasis in breast cancer Kang Yao, Zhu Xiaojun, Zhao Tingxiao, Liao Shiyao, Ji Lichen, Zhang Wei, Li Yanlei, Tian Jinlong, Ding Xiaoyan, Zhang Jun, Bi Qing, Lv Jun BMC Cancer.2023;[Epub] CrossRef
Diagnostic and Prognostic Role of 18F-Fluoroestradiol PET in Metastatic Breast Cancer: The Second Youth of an Older Theranostic Concept Francesco Fiz, Gianluca Bottoni, Giorgio Treglia, Pierpaolo Trimboli, Arnoldo Piccardo Journal of Clinical Medicine.2022; 11(13): 3589. CrossRef
Prominin 1 Significantly Correlated with Bone Metastasis of Breast Cancer and Influenced the Patient’s Prognosis Cheng-cheng Yu, Yi-nan Wu, Kai-min Hu, Su-zhan Zhang, Ali Imran BioMed Research International.2022; 2022: 1. CrossRef
Development of local injectable, bone-targeting nanocarriers of triptolide for treatment of bone-only metastasis Wucheng Wen, Pengbo Guo, Hui Yi Xue, Ho Lun Wong International Journal of Pharmaceutics.2022; 625: 122092. CrossRef
Clinical Characteristics, Prognostic Factors and Treatment Outcomes of Patients with Bone-Only Metastatic Breast Cancer Lina Marie, Dina Braik, Nayef Abdel-Razeq, Hala Abu-Fares, Ahmad Al-Thunaibat, Hikmat Abdel-Razeq Cancer Management and Research.2022; Volume 14: 2519. CrossRef
Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies Lulian Pang, Chen Gan, Jian Xu, Yingxue Jia, Jiaying Chai, Runze Huang, Anlong Li, Han Ge, Sheng Yu, Huaidong Cheng Cancers.2022; 14(23): 5727. CrossRef
Is there a role for locoregional treatment of the primary tumor in de novo metastatic breast cancer in the era of tailored therapies? E. Pons-Tostivint, E. Alouani, Y. Kirova, F. Dalenc, C. Vaysse Critical Reviews in Oncology/Hematology.2021; 157: 103146. CrossRef
Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Su-Jin Koh, Jaekyung Cheon, Joohyuk Sohn, Gun Min Kim, Keun Seok Lee, Sung Hoon Sim, In Hae Park, Sung-Bae Kim European Journal of Cancer.2021; 144: 341. CrossRef
Analysis of genomics and immune infiltration patterns of epithelial-mesenchymal transition related to metastatic breast cancer to bone Shuzhong Liu, An Song, Yunxiao Wu, Siyuan Yao, Muchuan Wang, Tong Niu, Chengao Gao, Ziquan Li, Xi Zhou, Zhen Huo, Bo Yang, Yong Liu, Yipeng Wang Translational Oncology.2021; 14(2): 100993. CrossRef
Trefoil factor-1 upregulation in estrogen-receptor positive breast cancer correlates with an increased risk of bone metastasis Chiara Spadazzi, Laura Mercatali, Mark Esposito, Yong Wei, Chiara Liverani, Alessandro De Vita, Giacomo Miserocchi, Elisa Carretta, Michele Zanoni, Claudia Cocchi, Alberto Bongiovanni, Federica Recine, Yibin Kang, Toni Ibrahim Bone.2021; 144: 115775. CrossRef
Diagnosis and referral of adults with suspected bony metastases Samantha Downie, Elizabeth Bryden, Fergus Perks, A Hamish RW Simpson BMJ.2021; : n98. CrossRef
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis Francesco Schettini, Mario Giuliano, Fabiola Giudici, Benedetta Conte, Pietro De Placido, Sergio Venturini, Carla Rognoni, Angelo Di Leo, Mariavittoria Locci, Guy Jerusalem, Lucia Del Mastro, Fabio Puglisi, PierFranco Conte, Michelino De Laurentiis, Lajos Cancers.2021; 13(6): 1458. CrossRef
Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT Gianluca Bottoni, Arnoldo Piccardo, Francesco Fiz, Giacomo Siri, Federica Matteucci, Andrea Rocca, Oriana Nanni, Manuela Monti, Etienne Brain, Jean Louis Alberini, Bassam Dib, Gian Mauro Sacchetti, Chiara Saggia, Valentina Rossi, Nadia Harbeck, Rachel Wue European Journal of Radiology.2021; 141: 109821. CrossRef
Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis Daniel Reinhorn, Raz Mutai, Rinat Yerushalmi, Assaf Moore, Eitan Amir, Hadar Goldvaser The Breast.2021; 58: 173. CrossRef
Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer Kerui Wu, Jiamei Feng, Feng Lyu, Fei Xing, Sambad Sharma, Yin Liu, Shih-Ying Wu, Dan Zhao, Abhishek Tyagi, Ravindra Pramod Deshpande, Xinhong Pei, Marco Gabril Ruiz, Hiroyuki Takahashi, Shunsuke Tsuzuki, Takahiro Kimura, Yin-yuan Mo, Yusuke Shiozawa, Ravi Nature Communications.2021;[Epub] CrossRef
Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening? Adam S. Komorowski, Ellen Warner, Helen J. MacKay, Arjun Sahgal, Kathleen I. Pritchard, Katarzyna J. Jerzak Clinical Breast Cancer.2020; 20(1): e54. CrossRef
Radiation therapy for bone-only metastases in breast cancer patients: A GOCO survey of current clinical practice Marta Bonet, Virginia García, Núria Farré, Manel Algara, Blanca Farrús, Jaume Fernandez, Victoria Reyes, Arancha Eraso, Ana Álvarez, Maria José Cambra, Agustí Pedro, Jordi Vayreda, Claire Lemansky, Françoise Izar, Meritxell Arenas Reports of Practical Oncology & Radiotherapy.2020; 25(1): 113. CrossRef
MicroRNA-429 inhibits bone metastasis in breast cancer by regulating CrkL and MMP-9 Xinxin Zhang, Xiying Yu, Zhenguo Zhao, Zhennan Yuan, Peiqing Ma, Zhibin Ye, Liping Guo, Songfeng Xu, Libin Xu, Ting Liu, Huanmei Liu, Shengji Yu Bone.2020; 130: 115139. CrossRef
Metastatic Presentations of Previously Treated Early-Stage Breast Cancer Patients and Association With Survival Najla Itani, Nicole Grogan, Sarah Mott, Sneha Phadke Clinical Breast Cancer.2020; 20(3): 209. CrossRef
Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer Cynthia Huang Bartlett, Jack Mardekian, Matthew James Cotter, Xin Huang, Zhe Zhang, Christina M. Parrinello, Ariel Bulua Bourla, Apar Kishor Ganti PLOS ONE.2020; 15(4): e0227256. CrossRef
International Framework for Red Flags for Potential Serious Spinal Pathologies Laura M. Finucane, Aron Downie, Christopher Mercer, Susan M. Greenhalgh, William G. Boissonnault, Annelies L. Pool-Goudzwaard, Jason M. Beneciuk, Rachel L. Leech, James Selfe Journal of Orthopaedic & Sports Physical Therapy.2020; 50(7): 350. CrossRef
Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer Liang Jin, Kai Chen, Cui Tan, Jianbin Li, Jiayue Luo, Yaping Yang, Yudong Li, Shunying Li, Liling Zhu, Yue Hu, Fengtao Liu, Qiuting You, Min Peng, Zefei Jiang, Qiang Liu The Oncologist.2020; 25(8): e1170. CrossRef
Imaging diagnosis of metastatic breast cancer Filippo Pesapane, Kate Downey, Anna Rotili, Enrico Cassano, Dow-Mu Koh Insights into Imaging.2020;[Epub] CrossRef
Tamoxifen Rechallenge Decreases Metastatic Potential but Increases Cell Viability and Clonogenicity in a Tamoxifen-Mediated Cytotoxicity-Resistant Subline of Human Breast MCF7 Cancer Cells Yung-Chieh Chang, Chun Hei Antonio Cheung, Yao-Lung Kuo Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials Richard S. Finn, Massimo Cristofanilli, Johannes Ettl, Karen A. Gelmon, Marco Colleoni, Carla Giorgetti, Eric Gauthier, Yuan Liu, Dongrui R. Lu, Zhe Zhang, Cynthia Huang Bartlett, Dennis J. Slamon, Nicholas C. Turner, Hope S. Rugo Breast Cancer Research and Treatment.2020; 184(1): 23. CrossRef
Innovative Options for Bone Metastasis Treatment: An Extensive Analysis on Biomaterials-Based Strategies for Orthopedic Surgeons Ania Naila Guerrieri, Monica Montesi, Simone Sprio, Roberta Laranga, Laura Mercatali, Anna Tampieri, Davide Maria Donati, Enrico Lucarelli Frontiers in Bioengineering and Biotechnology.2020;[Epub] CrossRef
The influence of breast cancer subtype on survival after palliative radiation for osseous metastases Mohamed K. Abdelhakiem, Candice Johnstone, Carmen Bergom, Adam Currey, Jared R. Robbins Cancer Medicine.2020; 9(23): 8979. CrossRef
Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics Jin-Xiao Ren, Yue Gong, Hong Ling, Xin Hu, Zhi-Ming Shao Breast Cancer Research and Treatment.2019; 173(1): 225. CrossRef
Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer: A real-world observational study Kang Wang, Yang Shi, Zhu-Yue Li, Ye-Lei Xiao, Jie Li, Xiang Zhang, Hong-Yuan Li European Journal of Surgical Oncology.2019; 45(8): 1364. CrossRef
The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis Ricardo Romero-Moreno, Kimberly J. Curtis, Thomas R. Coughlin, Maria Cristina Miranda-Vergara, Shourik Dutta, Aishwarya Natarajan, Beth A. Facchine, Kristen M. Jackson, Lukas Nystrom, Jun Li, William Kaliney, Glen L. Niebur, Laurie E. Littlepage Nature Communications.2019;[Epub] CrossRef
Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study Guenther G. Steger, Adriana Dominguez, Natalia Dobrovolskaya, Francesco Giotta, Nicole Tubiana-Mathieu, Martin Pecherstorfer, Antonio Ardizzoia, Maria Blasinska-Morawiec, Enrique Espinosa, Gustavo Villanova Clinical Breast Cancer.2018; 18(1): e41. CrossRef
Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010 Judith A. Malmgren, Musa Mayer, Mary K. Atwood, Henry G. Kaplan Breast Cancer Research and Treatment.2018; 167(2): 579. CrossRef
Breast cancer bone metastases: pathogenesis and therapeutic targets Naomi Brook, Emily Brook, Arun Dharmarajan, Crispin R. Dass, Arlene Chan The International Journal of Biochemistry & Cell Biology.2018; 96: 63. CrossRef
Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data Hongwei Zhang, Wei Zhu, Ewelina Biskup, Weige Yang, Ziang Yang, Hong Wang, Xiaochun Qiu, Chengjiao Zhang, Guangxia Hu, Guangfu Hu Journal of Bone Oncology.2018; 11: 38. CrossRef
Breast osteoblast-like cells: a new biomarker for the management of breast cancer Manuel Scimeca, Nicoletta Urbano, Rita Bonfiglio, Orazio Schillaci, Elena Bonanno British Journal of Cancer.2018; 119(9): 1129. CrossRef
Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer Akiko Ogiya, Kieko Yamazaki, Rie Horii, Tadahiko Shien, Yoshiya Horimoto, Norikazu Masuda, Touko Inao, Mitsuchika Hosoda, Naoko Ishida, Tomofumi Osako, Masato Takahashi, Yumi Endo, Yuichiro Miyoshi, Hiroyuki Yasojima, Nobumoto Tomioka, Hiroko Yamashita Breast Cancer.2017; 24(3): 473. CrossRef
Pattern of metastatic spread and subcategories of breast cancer Catharina Bartmann, Manfred Wischnewsky, Tanja Stüber, Roland Stein, Mathias Krockenberger, Sebastian Häusler, Wolfgang Janni, Rolf Kreienberg, Maria Blettner, Lukas Schwentner, Achim Wöckel, Joachim Diessner Archives of Gynecology and Obstetrics.2017; 295(1): 211. CrossRef
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid Claudia Omarini, Maria E. Filieri, Roberta Depenni, Giulia Grizzi, Stefano Cascinu, Federico Piacentini The Breast Journal.2017; 23(5): 610. CrossRef
The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone Aurélie Bellanger, Caterina F Donini, Julie A Vendrell, Jonathan Lavaud, Irma Machuca‐Gayet, Maëva Ruel, Julien Vollaire, Evelyne Grisard, Balázs Győrffy, Ivan Bièche, Olivier Peyruchaud, Jean‐Luc Coll, Isabelle Treilleux, Véronique Maguer‐Satta, Véroniqu The Journal of Pathology.2017; 242(1): 73. CrossRef
Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis I Bado, Z Gugala, S A W Fuqua, X H-F Zhang Oncogene.2017; 36(32): 4527. CrossRef
Which red flags aid the early detection of metastatic bone disease in back pain? Laura Finucane, Susan Greenhalgh, James Selfe Physiotherapy Practice and Research.2017; 38(2): 73. CrossRef
Prognostic utility of FDG PET/CT and bone scintigraphy in breast cancer patients with bone-only metastasis Soyeon Park, Joon-Kee Yoon, Su Jin Lee, Seok Yun Kang, Hyunee Yim, Young-Sil An Medicine.2017; 96(50): e8985. CrossRef
Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Shinji Ohno Clinical Breast Cancer.2016; 16(4): 238. CrossRef
Quality of life and symptom burden in patients with metastatic breast cancer Christine Ecclestone, Ronald Chow, Natalie Pulenzas, Liying Zhang, Angela Leahey, Julia Hamer, Carlo DeAngelis, Gillian Bedard, Rachel McDonald, Anchal Bhatia, Janet Ellis, Eileen Rakovitch, Sherlyn Vuong, Edward Chow, Sunil Verma Supportive Care in Cancer.2016; 24(9): 4035. CrossRef
Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer Joachim Diessner, Manfred Wischnewsky, Tanja Stüber, Roland Stein, Mathias Krockenberger, Sebastian Häusler, Wolfgang Janni, Rolf Kreienberg, Maria Blettner, Lukas Schwentner, Achim Wöckel, Catharina Bartmann BMC Cancer.2016;[Epub] CrossRef
Prolactin receptor in breast cancer: marker for metastatic risk Carrie S Shemanko Journal of Molecular Endocrinology.2016; 57(4): R153. CrossRef
Clinical Characteristics and Outcome of Bone-Only Metastasis in Inflammatory and Noninflammatory Breast Cancers Megumi Kai, Takahiro Kogawa, Diane D. Liu, Tamer M. Fouad, Kazuharu Kai, Naoki Niikura, Limin Hsu, Jie S. Willey, Richard L. Theriault, Vicente Valero, Naoto T. Ueno Clinical Breast Cancer.2015; 15(1): 37. CrossRef
Loading Dose Ibandronate Versus Standard Oral Ibandronate in Patients With Bone Metastases From Breast Cancer Iain R. Macpherson, Caroline Bray, Carol Hopkins, Rosemary A. Hannon, Liz-Anne Lewsley, Diana M. Ritchie, Peter Canney Clinical Breast Cancer.2015; 15(2): 117. CrossRef
Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care? D.K. Woolf, A.R. Padhani, A. Makris Annals of Oncology.2015; 26(6): 1048. CrossRef
Survival time according to the year of recurrence and subtype in recurrent breast cancer Masahiro Nakano, Mamiko Fujisue, Rumiko Tashima, Yasuhiro Okumura, Yasuyuki Nishiyama, Tomofumi Ohsako, Yasuo Toyozumi, Nobuyuki Arima, Reiki Nishimura The Breast.2015; 24(5): 588. CrossRef
Cases of Bone-only Metastasis in Recurrent Breast Cancer Yoko MAEKAWA, Shintaro TAKAO, Koichi HIROKAGA, Mayuko MIKI, Sachiko YOSHIDA Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2014; 75(6): 1484. CrossRef
Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors June Koo Lee, Seock-Ah Im, Daewon Lee, Ji-Yeon Kim, Yoojoo Lim, Eunyoung Lee, Hyeong-Gon Moon, Tae-Yong Kim, Sae-Won Han, Do-Youn Oh, Se-Hoon Lee, Wonshik Han, Dong-Wan Kim, Tae-You Kim, Dong-Young Noh Journal of Breast Cancer.2013; 16(1): 66. CrossRef
Incidence, consequences and treatment of bone metastases in breast cancer patients—Experience from a single cancer centre I. Kuchuk, B. Hutton, P. Moretto, T. Ng, C.L. Addison, M. Clemons Journal of Bone Oncology.2013; 2(4): 137. CrossRef
Zooming in on the schedule of bone-modifying drugs Miguel Martin, Sara López-Tarruella The Lancet Oncology.2013; 14(7): 575. CrossRef
Bone metastases: assessment, management and treatment options Carole Farrell British Journal of Nursing.2013; 22(Sup7): S4. CrossRef
Limites de la scintigraphie osseuse dans le suivi des métastases osseuses du carcinome mammaire : étude du centre tunisien K. Chatti, A. Harrabi, I. Chabchoub, T. Kamoun, R. Sfar, M. Nouira, M.B. Fredj, N. Ayachi, S.B. Ahmed, H. Essabbah Médecine Nucléaire.2012; 36(10): 574. CrossRef
PURPOSE The increased expression of cyclooxygenase (COX)-2 has been implicated in the development and progression of human cancer. This study investigated the COX-2 expression in colorectal cancer, and its relationships with tumor angiogenesis and the clinicopathological factors. MATERIALS AND METHODS: The expression of the COX-2 protein and microvessel density were evaluated, using immunohistochemical methods, in 21 normal colonic mucosa and 190 human colorectal carcinomas. Correlations between COX-2 expression and microvessel density, as well as various clinicopathological factors, were studied in colorectal carcinomas. RESULTS: The COX-2 protein expression in epithelial cells was increased in 169 of the 190 adenocarcinoma cases (88.9%), but in only 1 of the 21 (4.8%) normal mucosa cases. The COX-2 expression was significantly increased in the differentiated compared with the undifferentiated colorectal carcinomas (p<0.05), and significantly correlated with the depth of invasion and microvessel density (p<0.05). Rectal cancers had more COX-2 positive cases than the colon cancers (p<0.05). However, there were no significant differences in the tumor size and the presence of lymphatic or vascular invasion. CONCLUSION: The overexpression of cyclooxygenase-2 in colorectal carcinomas seems to play a role in the invasion and angiogenesis of the tumors, so may be a useful marker of the prognosis. The prominent expression was also demonstrated in differentiated colorectal cancers.
Citations
Citations to this article as recorded by
Expression of Cyclooxygenase (COX)-2 as a Prognostic Factor in Nasopharyngeal Cancer Kyubo Kim, Hong-Gyun Wu, Suk Won Park, Chong Jai Kim, Charn Il Park Cancer Research and Treatment.2004; 36(3): 187. CrossRef
PURPOSE Epstein-Barr virus(EBV) exists in the human population in two genetic forms, usually referred to as type 1 and type 2 which have been defined on the basis of sequence divergence in the EBNA-2 and EBNA-3 family genes.
In this study, we were intended to investigate whether the subtypes of EBV in malignant lymphoma in Korea were associated with specific disease entities and geographical distribution. MATERIALS AND METHODS Biopsy samples obtained from 18 Korean patients with malignant lymphoma including Hodgkin's disease(3 cases), B cell lymphoma(1 case), and NK/T cell lymphoma(14 cases) were analyzed to determine the subtype of EBV infected therein. DNA was extracted from formalin-fixed, paraffin-embeded tissues by ordinary method and specific viral sequences were sought using the polymerase chain reaction(PCR) and Southern blot hybridization assay.
Oligonucleotide primers used for examination of EBV strain type were derived from the EBNA-3B and EBNA-3C coding regions. As a control, four cases of reactive hyperplasia were analyzed. RESULTS The two of four reactive hyperplasia cases were associated with type 1 and the rest of two cases with both types. Among the 18 cases with malignant lymphoma, thirteen cases(72%) had type 1, one(6%) had type 2, and four(22%) had dual infections with both types. In case of NK/T cell lymphoma(14 cases) occupying 78% of 18 biopsy samples, 86%(12 cases) were associated with type 1, 7%(1 case) with type 2, and 7%(1 case) with both types. In case of Hodgkin's disease, all of three cases had both types. B cell lymphoma taking only one case of twenty two cases was determined as type 1. CONCLUSION These observations indicated that type 1 EBV was predominant in Korean patients with malignant lymphoma, especially NK/T cell lymphoma and showed high frequency of dual viral infections(22%) in Hodgkin's disease as well as in reactive hyperplasia.